OVID
Ovid Therapeutics Inc

6,071
Mkt Cap
$98.84M
Volume
1.7M
52W High
$2.01
52W Low
$0.2425
PE Ratio
-2.59
OVID Fundamentals
Price
$1.39
Prev Close
$1.37
Open
$1.36
50D MA
$1.42
Beta
1.01
Avg. Volume
1.98M
EPS (Annual)
-$0.3728
P/B
1.77
Rev/Employee
$24,608.70
Loading...
Loading...
News
all
press releases
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.
Zacks·12d ago
News Placeholder
More News
News Placeholder
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Zacks·22d ago
News Placeholder
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·26d ago
News Placeholder
Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why
The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.
Stocktwits·29d ago
News Placeholder
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
chainwire·6mo ago
News Placeholder
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Latest Ratings for OVID DateFirmActionFromTo Aug 2021CitigroupMaintainsNeutral Apr 2021Cantor FitzgeraldDowngradesOverweightNeutral Dec 2020CitigroupDowngradesBuyNeutral View More Analyst...
Benzinga·1y ago
News Placeholder
H.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ovid Therapeutics (OVID Research Report), with a price...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial Outlook
TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today. Ritu Baral has given his Buy rating due t...
TipRanks Financial Blog·1y ago

Latest OVID News

View

Advertisement|Remove ads.

Advertisement|Remove ads.